MX9203950A - Composicion reguladora de apoptosis. - Google Patents

Composicion reguladora de apoptosis.

Info

Publication number
MX9203950A
MX9203950A MX9203950A MX9203950A MX9203950A MX 9203950 A MX9203950 A MX 9203950A MX 9203950 A MX9203950 A MX 9203950A MX 9203950 A MX9203950 A MX 9203950A MX 9203950 A MX9203950 A MX 9203950A
Authority
MX
Mexico
Prior art keywords
apoptosis
regulatory composition
regulatory
composition
Prior art date
Application number
MX9203950A
Other languages
English (en)
Spanish (es)
Inventor
Satoru Nakai
Kuotoku Aihara
Hitomi Mori
Hiroyuki Ichikawa
Seiji Akamatsu
Michiaki Tominaga
Masakazu Adachi
Fumio Saito
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX9203950A publication Critical patent/MX9203950A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX9203950A 1991-07-03 1992-07-03 Composicion reguladora de apoptosis. MX9203950A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16258791 1991-07-03
JP3346992 1992-02-20
JP4571892 1992-03-03
JP10058592 1992-03-25

Publications (1)

Publication Number Publication Date
MX9203950A true MX9203950A (es) 1993-05-01

Family

ID=27459795

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203950A MX9203950A (es) 1991-07-03 1992-07-03 Composicion reguladora de apoptosis.

Country Status (11)

Country Link
US (5) US5672603A (show.php)
EP (1) EP0552373B1 (show.php)
KR (1) KR100196368B1 (show.php)
AU (1) AU648690B2 (show.php)
CA (1) CA2090876A1 (show.php)
DE (1) DE69230131T2 (show.php)
DK (1) DK0552373T3 (show.php)
ES (1) ES2138971T3 (show.php)
MX (1) MX9203950A (show.php)
TW (1) TW229157B (show.php)
WO (1) WO1993000902A1 (show.php)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004504A1 (fr) * 1992-08-19 1994-03-03 Otsuka Pharmaceutical Co., Ltd. Regulateur d'apoptose
EP0638311A4 (en) * 1993-03-02 1997-05-02 Otsuka Pharma Co Ltd REJECTION INHIBITOR FOR TRANSPLANTATIONS AND INTERLEUKIN PRODUCTION INHIBITOR 1.
GB9311132D0 (en) * 1993-05-28 1993-07-14 Eisai London Res Lab Ltd Control of cell death
KR100191191B1 (ko) * 1993-10-21 1999-06-15 오쓰까 아끼히꼬 인터루킨-8합성억제의 카르보스티릴 유도체
US5504093A (en) * 1994-08-01 1996-04-02 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting nucleoside and nucleobase transport in mammalian cells, and method for inhibition of DNA virus replication
MX9603868A (es) * 1995-01-11 1997-03-29 Otsuka Pharma Co Ltd Composicion farmaceutica de derivados de indeno para la regulacion de la apoptosis.
WO1998046229A1 (en) * 1995-06-21 1998-10-22 Otsuka Pharmaceutical Co., Ltd. Il-8 and mcaf production inhibitors
JPH0971532A (ja) * 1995-09-06 1997-03-18 Otsuka Pharmaceut Co Ltd 発癌抑制剤
US5700803A (en) * 1995-12-12 1997-12-23 Otsuka Pharmaceutical Co., Ltd. Method for reducing infarct size in subjects afflicted with ischemic heart disease
WO1998048807A1 (en) * 1997-04-25 1998-11-05 Otsuka Pharmaceutical Co., Ltd. Hyaluronate synthesis inhibitors
US6008209A (en) * 1997-04-28 1999-12-28 Hoffmann-La Roche Inc. Method of using vitamin D3 analogs with bis C-20 side chains
US6544972B1 (en) 1997-09-25 2003-04-08 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US6281191B1 (en) 1997-12-29 2001-08-28 Vladimir I. Slesarev Compositions and methods for treating hepatitis-C
FR2774289B1 (fr) 1998-02-03 2002-05-24 Goemar Lab Sa Medicament pour le traitement des dereglements de l'apoptose
EP2311490A3 (en) 1998-07-13 2011-05-04 Board of Regents, The University of Texas System Uses of antibodies to aminophospholipids for cancer treatment
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
US6277974B1 (en) 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
WO2003053222A2 (en) * 2001-12-20 2003-07-03 Cogent Neuroscience, Inc. Methods for treating conditions, disorders, or diseases involving cell death
NZ596825A (en) 2002-07-15 2013-06-28 Univ Texas Duramycin peptides and their use in imaging
JP2006510740A (ja) * 2002-11-07 2006-03-30 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 出血と関連した神経系障害を治療する方法
WO2008109433A2 (en) 2007-03-02 2008-09-12 The Cleveland Clinic Foundation Anti-angiogenic peptides
US20060204481A1 (en) * 2003-04-02 2006-09-14 Steer Clifford J Methods of promoting cell viability
DK1718283T3 (da) 2004-01-22 2013-04-22 Univ Miami Topisk co-enzyme Q10 formuleringer og fremgangsmåder for anvendelse.
US20080194531A1 (en) * 2005-02-10 2008-08-14 Steer Clifford J Methods for Treating Visual Disorders
EP2614837A1 (en) 2007-11-09 2013-07-17 Affitech Research AS Anti-VEGF antibody compositions and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5430184A (en) * 1977-08-10 1979-03-06 Otsuka Pharmaceut Co Ltd 3,4-dihydrocarbostyril derivative
JPS6038384B2 (ja) * 1978-03-24 1985-08-31 大塚製薬株式会社 チオセミカルバゾン誘導体
JPS5777676A (en) * 1980-10-31 1982-05-15 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5793962A (en) * 1980-12-01 1982-06-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS62135423A (ja) * 1985-12-09 1987-06-18 Otsuka Pharmaceut Co Ltd 低酸素症改善剤

Also Published As

Publication number Publication date
AU648690B2 (en) 1994-04-28
HK1004469A1 (en) 1998-11-27
KR100196368B1 (ko) 1999-06-15
US5925640A (en) 1999-07-20
WO1993000902A1 (fr) 1993-01-21
DE69230131T2 (de) 2000-03-02
DK0552373T3 (da) 1999-12-27
US5872120A (en) 1999-02-16
EP0552373A4 (en) 1993-09-22
TW229157B (show.php) 1994-09-01
US5916890A (en) 1999-06-29
KR930702002A (ko) 1993-09-08
ES2138971T3 (es) 2000-02-01
DE69230131D1 (de) 1999-11-18
US5672603A (en) 1997-09-30
EP0552373A1 (en) 1993-07-28
EP0552373B1 (en) 1999-10-13
US5798358A (en) 1998-08-25
AU2231792A (en) 1993-02-11
CA2090876A1 (en) 1993-01-04

Similar Documents

Publication Publication Date Title
MX9203950A (es) Composicion reguladora de apoptosis.
MX9201819A (es) Compuestos benzoheterociclicos.
MX9202978A (es) Compuestos de amino-4-aril-tiazoles.
MX9200260A (es) Composicion catalitica
NL300035I1 (nl) Gesubstitueerde thiahzolidinedionderivaten.
MX9206423A (es) Composicion de perfume.
MX9102436A (es) Derivados de alfa/oxoacetamida.
FI915768L (fi) Komposition foer rengoering av maolningar.
FI921262L (fi) 4-aryltiazol- eller 4-arylimidazolderivat
FI933467A7 (fi) Koostumus
BR9200270A (pt) Construcao de embarcacao
DE69104947D1 (de) Verhütung von Kesselstein.
ITMI912655A1 (it) Combinazione di estrusore-calandra.
MX9205003A (es) Derivados novedosos de benzopirano.
FI924643A7 (fi) Braenslekomposition
MX9100245A (es) Composicion de revestimiento reticulable.
FI925166A0 (fi) Proteolytiska enzymer inhibiterande sackarinderivat
FI922697L (fi) Komposition foer avlaegsnande av polymerbelaeggningar
DE69225104D1 (de) PCT-Zusammensetzung
MX9204370A (es) Derivados de pirazol.
MX9202690A (es) Nuevos compuestos de cefem.
NO924745D0 (no) Benzofuraner
MX9200872A (es) Composicion de bis-bibenzimidazol.
NO921942L (no) Benzofuranderivater
FI925827L (fi) Tvaerbindbar polymerisk komposition